Low levels of ATM in breast cancer patients with clinical radiosensitivity.
Low levels of ATM in breast cancer patients with clinical radiosensitivity.
复制标题
DOI：
10.1186/2041-9414-1-9
复制
发表时间：
2010-06-24
期刊：
影响因子：
--
通讯作者：
Clarke RA
中科院分区：
文献类型：
--
作者：
Fang Z;Kozlov S;McKay MJ;Woods R;Birrell G;Sprung CN;Murrell DF;Wangoo K;Teng L;Kearsley JH;Lavin MF;Graham PH;Clarke RA
癌症的辅助放疗可能会对正常组织产生严重的不良副作用。在这方面，具有ATM（共济失调毛细血管扩张症）蛋白/基因异常的个体是特别感兴趣的，因为它们可能处于乳腺癌和临床放射敏感性两者的风险中。特定ATM基因突变与这些病理学的关联已得到充分证实，然而，关于ATM蛋白的病理学阈值存在不确定性。半定量免疫印迹法提供了一种可靠的和可重复的方法来比较ATM蛋白的水平为一个罕见的队列的20名癌症患者选择的基础上，他们的严重不良正常组织反应的放射治疗。我们发现，4/12（33%）的乳腺癌患者在放疗后有严重的不良正常组织反应，ATM蛋白水平< 55%，与非反应者对照组的平均值相比。ATM突变通常被认为是乳腺癌和临床放射敏感性的低风险等位基因。根据本文报道的结果，我们提出了一个暂定的ATM蛋白阈值约为55%的乳腺癌患者的临床放射敏感性的高风险。
Adjuvant radiotherapy for cancer can result in severe adverse side effects for normal tissues. In this respect, individuals with anomalies of the ATM (ataxia telangiectasia) protein/gene are of particular interest as they may be at risk of both breast cancer and clinical radiosensitivity. The association of specific ATM gene mutations with these pathologies has been well documented, however, there is uncertainty regarding pathological thresholds for the ATM protein. Semi-quantitative immuno-blotting provided a reliable and reproducible method to compare levels of the ATM protein for a rare cohort of 20 cancer patients selected on the basis of their severe adverse normal tissue reactions to radiotherapy. We found that 4/12 (33%) of the breast cancer patients with severe adverse normal tissue reactions following radiotherapy had ATM protein levels < 55% compared to the mean for non-reactor controls. ATM mutations are generally considered low risk alleles for breast cancer and clinical radiosensitivity. From results reported here we propose a tentative ATM protein threshold of ~55% for high-risk of clinical radiosensitivity for breast cancer patients.